# Relationship between obstructive sleep apnea and human leukocyte antigen variants

**Ayse Gul Zamani[1], Sebnem Yosunkaya[2], Adil Zamani[2], Hulya Vatansev [2], Ahmet Burak Arslan[1], Mahmut Selman Yildirim[1]**

[1] Department of Medical Genetics, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey

[2]Department of Pulmonary Medicine, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey

syosunkaya@gmail.com
adzamani@hotmail.com
hulyavatansev@hotmail.com
drabarslan@gmail.com
drmselman@hotmail.com

**Word number of manuscript: 3674**

**Corresponding Author:**
**Assoc.Prof.Dr. Ayse Gul Zamani**

**ORCID ID: 0000-0003-0329-9047**
Department of Medical Genetics,
Meram Medical Faculty,
Necmettin Erbakan University,
42090, Meram/Konya/Turkey
E-mail: agzamani@yahoo.com
GSM: +905374028087
Phone: +90 332 2236652
Fax: +90 332 2236181

**ABSTRACT**

**Background and aim:** The obstructive sleep apnea (OSA) is a common, complex and polygenic disease and it has high risk of serious complications. The human leukocyte antigen (HLA) system plays a crucial role in the regulation of immune function by discriminating self from non-self. In recent years there has been rapid advancement in "Next Generation Sequencing" technology. It enables the detection of HLA alleles in four or even six digits, providing a high level of precision. The aim of the present study was to investigate the genetic variants at HLA-A,-B,-C,-DQB1 and -DRB1 loci in OSA patients and unrelated healthy individuals by targeted NGS in the Turkish population.

**Materials methods:** Fifty newly diagnosed patients with OSA and 50 control subjects were enrolled in the study. OSA diagnosis was made by utilizing the apnea-hypopnea index (AHI)≥5 in overnight polysomnography (PSG). Blood samples were obtained in the morning, after PSG. Controls were randomly selected from healthy volunteers who had a low risk for OSA. Genotyping of HLA-A, B, C, DRB1 and DQB1 genes were performed by using next generation sequencing.

**Results:** HLA-A*02:01, HLA-C*03:03:01, HLA-C*14:03, HLA DRB1*04:05 alleles were found more frequently in OSA patients, but not in the controls (p=0.036, p=0.007, p=0.043 and 0.013, respectively). The allele frequencies of HLA-A*03:01 and HLA-B*35:02 were significantly higher in controls compared to OSA patients (p=0.024 and p=0.043).

**Conclusion:** These results suggest that HLA-A*02:01, HLA-C*03:03:01, HLA-C*14:03, HLA DRB1*04:05 alleles may play a predisposing role in the Turkish population with OSA. In addition, HLA-A*03:01 and HLA-B*35:02 alleles may be protective in this population.

**Key words:** OSA, HLA, Human leukocyte antigen typing, high resolution typing, next-generation sequencing, genotyping

## INTRODUCTION

Obstructive sleep apnea (OSA) is among the most prevalent of sleep-disordered breathing (SDB) types, characterized by recurrent episodes of partial or complete collapse of the upper airway during sleep, resulting in reduced (hypopnea) or absent (apnea) airflow lasting for at least 10 seconds and associated with either cortical arousal or a fall in blood oxygen saturation. The presence and severity of the disease is determined by the amount of respiratory events per hour during sleep: apnea-hypopnea index (AHI) (1). Moderate to severe disease affects up to 17% of middle-aged men and 9% of middle-aged women (2). Obesity is a major modifiable-risk factor and is present in approximately 70% of patients with OSA (3). Non modifiable risk factors for the development OSA are age, gender (male), ethnicity, anatomical abnormalities of craniofacial regions and upper airway, a thick neck with circumference more than 17 inches(4). This are thought to be affected by genetic factors. There is growing evidence that genetic factors, and their interaction with environmental exposures, influence the development of OSA (5,6). Evidence from family-based and twin studies, as well as the association of specific hereditary craniofacial disorders and the Prader-Willi syndrome with OSA, indicate that the disease may have a genetic basis (5). However, the genetic basis of the disease is yet to be clearly identified.

It has been estimated that approximately 40% of the variance in the AHI may be explained by familial factors. It is likely that genetic factors associated with craniofacial structure, body fat distribution and neural control of the upper airway muscles interact to produce the OSA phenotype(6). Genetic factors were found to have a role in OSA development via pathways involved with ventilatory control, craniofacial anatomy, inflammation and immunity(7).

The HLA system plays a very important role in the regulation of immune function and in determining what is self or non-self. HLA, a group of genes encoding the major histocompatibility complex (MHC), have been reported to be associated with with more than

100 diseases, including common diseases--such as diabetes, rheumatoid arthritis, psoriasis, asthma(8,9). The HLA genes can be divided into two groups that encodes class I molecules(HLA-A,-B and-C) and class II molecules(HLA-DRA, -DRB1,-DQA1,-DQB1,-DPA1, and -DPB1). They are located within the MHC region in 6p21.3. There are more than 20,000 different alleles that are closely related to each other. Both Class I and Class II molecules take part in presenting short peptides to T lymphocytes. Class I molecules present not only naturally occuring peptides, but also different endogenously produced peptides, including mutated, damaged, degraded or misfolded proteins, and viral proteins to CD8-positive T lymphocytes. On the other hand, class II molecules present exogenously produced peptides such as bacterial proteins to CD4-positive T lymphocytes (9,10).

Serological methods can identify only a very small fraction of HLA alleles. Alleles with different DNA sequences can encode proteins with similar serological reactivity. Starting from the 1980s, sequencing of HLA genes led to a rapid increase in newly identified alleles. Identification of HLA type based on DNA sequence was therefore possible in addition to molecular typing, amino acid sequence and serological reactivity. Many HLA tissue typing laboratories around the world have adopted SSO (specific oligonucleotides), SSP (sequence specific primers) and Sanger sequencing methods for this purpose. However, SSO or SSP methods can only detect previously known alleles (10,11). Sanger sequencing is stepwise and cannot identify some heterozygous single nucleotise variations (SNVs), also is expensive and cumbersome. HLA alleles are reported between high resolution and low resolution scales, according to the typing method used. With serological typing, allele detection resolution will be low, and they are typically reported like “A * 01; A * 02” (2 digits) (as an example). SSO or SSP can only detect known alleles with high accuracy and 4 digits resolution. Whereas with NGS method, a result with high resolution is obtained, and alleles are defined as unique nucleotide sequences using all the numbers that define it, e.g. A * 01: 01: 01: 01 and A * 02:

07) (http://hla.alleles.org/).So, it enables the detection of alleles in four or even six digits. Next generation sequencing (NGS) technologies increase HLA typing speed, by analyzing large numbers of samples with higher resolution and with lower cost per sample (11).

The aim of the present study was to investigate the genetic variants at HLA-A,-B,-C,-DQB1 and -DRB1 loci in OSA patients and healthy individuals by NGS.

## MATERIALS AND METHODS

This case control study was carried out at the Department of Pulmonary Medicine and Department of Medical Genetics, of Necmettin Erbakan University, Meram Medical Faculty Hospital. The study was designed as a case-control study and approved by the Ethics Committee of Necmettin Erbakan University, Konya (2017/827). The study was supported by the Scientific Research Projects of Necmettin Erbakan University (Project no: 171218006).

Fifty newly diagnosed patients with OSA and 50 control subjects were enrolled in the study. Control group was composed of 50 volunteer healthy individuals who applied to the tissue laboratory to become a transplant donor. They were routinely analyzed, not related to each other, and were randomly selected. Control subjects had no previously diagnosed medical condition, or any symptom of OSA; all of them completed the Epworth Sleepiness Scale (ESS) questionnaire (12). A written informed consent was obtained from all participants.

### Exclusion Criteria for Patients

Patients diagnosed with other sleep disorders: central sleep apnea, sleep related hypoxemia, sleep related hypoventilation, narcolepsy, insomnia, cycardian rhythm disturbances, periodic leg movements and, with diseases that are known to be associated with OSA, such as Cushing's syndrome, acromegaly, neuromuscular disorders hypothyroidism and, with known severe pulmonary disease (asthma, COPD, bronchiectasis, etc.), individuals with airway

obstruction (FEV1 / FVC <70%) in pulmonary function tests according to GOLD criteria and, patients with any pathology on PA chest radiography were excluded from the study (13).

**Polysomnography Protocol**

All the patients included in the study were performed overnight polysomnography (PSG) examination using "SOMNOscreen plus, Somnomedics, Germany" brand PSG device in the sleep laboratory. PSG was done with 4-channel electroencephalography (EEG) (C3/A2, C4/A1, O1/A2, O2/A1), 2-channel electrooculography (EOG) (right and left), submentalelectromyography (EMG), current meter placed in the mouth and nose nasal cannula and thermistor, pulsoxymetry placed on the finger, tension sensitive belts placed on the thorax and abdomen, leg EMG recording placed on the tibialis anterior muscle, additional snore sensor and position sensors. Analysis and interpretation of PSG data were done by a sleep specialist in accordance with the standard technique. A decrease in airflow more than 90% compared to basal value for 10 seconds was defined as "apnea", and a decrease in air flow in the mouth and 30% compared to basal value accompanied by 3% desaturation or arousal for ≥10 sec. was defined as "hypopnea"(14).

**Apnea/Hypopnea Index**

Apnea-hypopnea index (AHI) value was calculated by dividing the total number of apnea and hypopnea episodes by sleep time (hours). In terms of disease severity; those with an AHI value of 0-5 were classified as "simple snoring", patients with an AHI value between 5 and 15 were classified as mild OSA, 16-30 as moderate, and those with AHI> 30 were classified as having severe OSA. In addition to the AHI value of the standard polysomnography reports of the people included in the study all night; minimum oxygen saturation (min SaO2): lowest oxygen saturation value during sleep; average oxygen saturation (avSaO2): the average value of the oxygen saturation recorded overnight; time SaO2 ≤ 90% (z SaO2 <90): the ratio of

90% of night-to-night sleep time to the entire sleep time; sleep efficiency (UE): the ratio of time spent asleep to time spent in bed; REM duration rate (% REM) The ratio of REM sleep time to the entire sleep time and NREM3 time ratio (NREM3 %) NREM3, ie the ratio of deep sleep to the entire sleep time was recorded for each patient(15).

**Epworth Sleepiness Scale (ESS)**

All patients and controls were asked to fill the Epworth Sleepiness Scale questionnaire at their initial interview. The Epworth sleepiness Scale is a test used to evaluate sleepiness subjectively. In this test, the probability of falling asleep in eight different situations is scored. Turkish version of this test is also validated. Participants who scored ten points or higher in this test, were considered to have daytime sleepiness (16).

**HLA Typing by NGS**

Peripheral blood genomic DNA was extracted using QIAamp DNA Blood Mini Kit, according to the manufacturer's instructions (QIAGEN, Germantown, Maryland). The quality and quantity of DNA was compared.

The samples were typed for HLA-A, -B, -C, -DRB1 and -DQB1 loci by next-generation sequencing in Illumina MiniSeq using MIA FORA NGS FLEX HLA typing kit (Bio Array Solutions Ltd., New Jersey) described elsewhere (17). The coverage for HLA-A, -B, and -C included all exons and introns, at least 200 base pairs of the 5′ UTR and 100–1100 base pairs of the 3′ UTR; coverage for -DRB1 included all exons, introns 2–6, at least 440 base pairs of the 5′ UTR, 12 base pairs of the 3′ UTR, 275 base pairs of intron 1 adjacent to exon 1, and 210 base pairs of intron 1 adjacent to exon 2; coverage for -DQB1 included exons 1–5 and introns 1–4; coverage for -DPB1 included exons 2–4 and introns 2–3(Figure 1)(18).

In brief, long range PCR was performed for HLA genes using 5–15 ng/µl of DNA. The concentration of each amplicon was determined using PicoGreen® assay. Balanced, pooled

amplicons were fragmented, end repaired and A-tailed. Samples were ligated with unique index-adaptors. The pooled, clean and index-adaptor ligated samples were purified using the Pippin Prep system, which selects DNA fragments with the desired range (500–900 bp). The amplified sequencing library was cleaned, quantified and prepared for Illumina sequencing. The average sequencing coverage generated was ≥40×. The sequencing data were analysed using MIA FORA NGS FLEX HLA Genotyping Software version 3.0 with reference to IPD-IMGT/HLA database release 3.27.0(19).

A mismatch filter eliminated alignments with mismatches or gaps and a paired-end filter increased specificity by requiring both ends to map to a single HLA reference. Then minimum coverage was computed for each allele candidate and allele pairs were computed as described in Wang et al. (17). Alleles were identified by variation in the coding sequence only.

**Statistical Analysis**

Continuous variables are expressed as the mean ± standard deviation. Comparisons were performed using t test or $\chi 2$ tests depending on data differences among groups. SPSS (v.22) program was used for the statistical analysis of the obtained data. The “allele frequency” of the HLA alleles was calculated for the patient and control groups and comparisons were made using the $\chi 2$ or Fisher’s exact test. Odds ratio (OD) and confidence interval were calculated. The difference was considered statistically significant when the *p* value was found as "<0.05".

**RESULTS**

The demographic characteristics and ESS scores of OSA patients and normal controls are detailed in Table 1. There were no significant difference between cases and controls group in terms of age, gender and BMI (all $p < 0.05$ ). There was only a significant difference between the two groups in terms of ESS scores. Polysomnographic data of OSA patients were given in table 2.

Comparative results of patient-control groups for this region are summarized in Table 3. There was a statistically significant difference between these groups in terms of HLA-A * 02: 01 and HLA-A * 03: 01 alleles (p = 0.036, p = 0.024). HLA-A * 02: 01 was observed more frequently in the patient group, while HLA-A * 03: 01 was more frequent in the control group. It was shown that the HLA-A * 02: 01 allele was susceptible to the disease and the HLA-A * 03: 01 allele was protective. The p value of the HLA-B * 35: 02 allele (p = 0.043) was statistically significant, HLA-B * 44: 03 allele is considered insignificant with p = 0.054. Nevertheless, it should be noted that this is a borderline value. The HLA-B * 35: 02 allele was evaluated as protective.HLA-C * 03: 03: 01 and HLA-C * 14: 03 alleles were observed more frequently in the patient group (p = 0.007, p = 0.043) and these alleles were predisposing to the disease, too. There was no statistically significant difference for HLA-DQB1 region. HLA DRB1 * 04: 05 allele (p = 0.013). was frequently observed in the patient group, was predisposing to the disease.

To summarize, HLA-A * 02: 01, HLA-C * 03: 03: 01, HLA-C * 14: 03, HLA DRB1 * 04: 05 alleles were found more frequently in OSA patients, but not in the controls (p=0.036, p=0.007, p=0.043 and 0.013, respectively). The allele frequencies of HLA-A * 03: 01 and HLA-B * 35: 02 were significantly higher in controls compared to OSA patients (p=0.024 and p=0.043).

## DISCUSSION

Many researchers have tried to find a genetic marker associated with OSA (5,6). Although there are several studies about other types of sleep disorders, it seems like there are limited number of studies investigating the relationship between HLA genes and OSA (Table 4). The first study that investigates this relationship was conducted in Japan.Yoshizawa et al. showed that the HLA-A2 allele had a higher frequency in the OSA patient group (composed of 32

male patients with OSA) when compared with normal controls(20). However, they could not suggest a thesis that could explain the underlying patho-physiological mechanism. Considering that the BMI rate is higher in patient group, this particular HLA-OSA relationship can be considered controversial (20). In another study conducted in Korea, 25 patients (24 men, 1 woman) were investigated and it was shown that there was a relationship with OSA and the HLA-DRB1 * 09 and HLA-A11 alleles. Additionally, the HLA-DRB1 * 08 allele was reported to be associated with the severity of OSA. (21). Another study in Northern Portugal found that the HLA-DRB1 * 03 allele was linked with the OSA. It was stated that the presence of these alleles in male and obese patients may be a predisposing factor for the development of OSA (22). Manzetto et al. showed that the presence of HLA-DRB1 * 0602 allele is related to the EEG findings of the patients. Theta waves during sleep stage 1 and low delta waves during sleep stage 1 and 2 were found to be different between patients harboring this allele and ones who are not. It has been stated that this allele is a potential marker affecting sleep physiology in patients diagnosed with OSA (23). Momany et al. Stated that the OSA and HLA-DQB1 * 0602 allele are related, while HLA-DRB1 * 15 allele is not (24). Brunetti et al. defined a relationship between the HLA-DRB1 * 15 allele and SDS, in their study on pediatric patients.They also stated that the expression of HLA-B65 allele was significantly higher in SDS patients and that there might be a possible relationship (25).

To date, it seems like there have been two studies which investigate the possible relationship between OSA and HLA genes in Turkey.The first of these was published in the year of 2003 and the frequency of the HLA-DRB1 * 15 allele was shown to be higher in patient group (26).In another study conducted in 2018, the frequency of HLA-DRB1 alleles was evaluated in OSA patients and it was reported that the DRB1 * 03 allele had a predisposing role and the HLA-DRB1 * 08 allele was associated with the severity of OSA (27).The studies conducted in the world and our country and the results of our study are summarized in Table 4. Amongst

those studies, a HLA region analysis as detailed as ours was only performed by Yoshizawa, Brunetti and Alfazer et al. In terms of methodology, Yoshizawa and Alfazer used the standard lymphocyte microcytotoxicity test, whereas Brunetti used the lymphocyte microcytotoxicity test for class I antigens and PCR/SSO test for class II antigens(20,25,26). Serological methods can identify only a very small fraction of HLA alleles. SSO or SSP methods can only detect previously known alleles (10,11). These tests are limited for being suitable only for two-step evaluation of the HLA polymorphic gene locus.In our study, the usage of NGS methodology enabled us to perform a 4/6-step evaluation of these aforementioned genes, which made it possible to determine all probable alleles.Since the HLA polymorphic alleles have been identified cumulated within the databases over the years; it is important to emphasize that the work of Yoshizawa took place approximately 25 years before our work and the work of Brunetti 10 years ago as well(20,25). Though it does not mean the data from these studies are invaluable, the fact that they were done with older techniques and without enough database support remains.

In our study; a significant difference of the frequency of HLA-A * 02: 01 and HLA-A * 02: 03 alleles (p = 0.036, p = 024) between patients and the control group was observed. HLA-A * 02: 01 was observed more frequently in the patient group, whereas HLA-A * 03: 01 was more often in the control group. The HLA-A * 02: 01 allele was shown to be predisposing to the disease, and the HLA-A * 03: 01 allele was shown to be protective.

Previously, Yoshizawa et al. has reported that the HLA-A * 02 allele is associated with OSA(20). In our study, the HLA-A * 02 allele was also found to be associated with OSA. However, the four-step NGS assessment enabled us to determine that the HLA-A * 02: 01 subgroup of this allele is the precise subgroup that predisposes to the disease; while the HLA-A * 03: 01 subgroup of the same allele is protective. It appears that Brunetti et al. did not find

a relationship with the HLA-A region(25). Apart from that, Lee et al. has stated that the HLA-A * 11 allele is predisposing for OSA(21).

The results of the analysis done for HLA-B region showed that the HLA-B * 35: 02 allele appears to be protective for the disease; since this allele was more frequently observed in controls. Regarding this region, Brunetti et al. showed that there is a relationship between the HLA-B * 65 region and the OSA(25). Such a result can be considered unique to Turkey since the HLA locus is a polymorphic gene region with important ethnic differences. In other studies conducted in our country (26,27), such a relation was not found. For the same region, the *p* value of the HLA-B * 44: 03 allele was found to be 0.054 and was considered as insignificant. This is quite a borderline value. Investigating this region by increasing the number of patients and control groups may provide a significant result.

For the HLA-C region; a statistically significant difference in terms of HLA-C * 03: 03: 01 and HLA-C * 14: 03 alleles was found ($p = 0.007$, $p = 0.043$). Both alleles were observed more frequently in the patient group and these alleles were thought to be predisposing to the disease. In studies on patients OSA no such link has been previously reported.

No allele related association was detected for the HLA-DQB region. However, Manzotte and Momany has previously reported in their study that there was a relationship between the HLA-DRB1 * 0602 allele and the incidence of OSA(23,24). They considered this allele as a predisposing allele. There was no such relationship in our study. In the analysis made for the HLA-DRB1 region, it was seen that there was a statistically significant difference between the groups for the HLA-DRB1 * 04: 05 allele ($p = 0.013$). This allele which is frequently observed in the patient group, and was thought to be predisposing to the disease. Tepebaşı and Silva reported that the HLA-DRB1 * 03 allele and the HLA-DRB1 * 09 allele were predisposing for OSA(22,27). There is no previous report of any kind of relation between DRB1*04:05 allele and OSA.

The main limitation of this study is that we were only able to include a small number of individuals in both the patient and control groups. It is rather expensive to conduct such a study and the funding capabilities of our center is limited. But in spite of this unfortunate limitation, interesting and important results were obtained, but it is clear that it does not obliviate the fact that larger and more statistically powerful studies could help enlighten this relationship further.

**Conclusions and recommendations**

Gene regions of HLA-A, -B, -C, -DQB1 and -DRB1 were studied by NGS. HLA-A * 02: 01 HLA-C * 03: 03: 01, HLA-C * 14: 03, HLA DRB1 * 04: 05 alleles were found to be associated with OSAS pathogenesis. These alleles were considered as disease-predisposing. On the other hand, HLA-A * 03: 01 and HLA-B * 35: 02 alllels were observed at higher frequency in normal controls and were considered as protective alleles. Considering the polymorphic nature and ethnic differences of the MHC gene region, these previously unreported alleles are of importance and might be spesific to our region as well.

In our study, an important link between HLA and OSAS has been shown. There have been previous associations of these two in the past as well, but nevertheless, the number of studies conducted in regard of this particular relation both in our country and in the world is quite low. There is still a need for multicentric studies with high numbers of patients to further enlight this concordance.

Furthermore, it should be noted that our study employed the most sensitive DNA sequence analysis method that is used in the world as of now. And it is the first study that investigates the HLA-OSA relationship with this particular methodology. NGS studies aimed for HLA region allow for more accurate and higher resolution analysis compared with other methods. Although it is more expensive compared to other methods, it enables the detection of alleles

in four or even six digits, providing a high level of precision. Since ethnic differences for this gene region is quite well-known, it is clear that conducting more studies in different parts of the world employing NGS method for this purpose will be beneficial.

**Acknowledgements**

The study was supported by the Scientific Research Projects of Necmettin Erbakan University (Project no: 171218006).

## REFERENCES


1. American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL: AASM; 2014.

2. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013; 177:1006-14.

3. Fritscher LG, Mottin CC, Canani S, Chatkin JM. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg. 2007; 17:95-9.

4. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008; 5:136-43.

5. Redline S, Tishler PV. The genetics of sleep apnea. Sleep Med Rev. 2000;4 :583-602.

6. Dudley KA, Patel SR. Disparities and genetic risk factors in obstructive sleep apnea. Sleep Med. 2016; 18:96-102.

7. Yee BJ, Buchanan PR, Mahadev S, Banerjee D, Liu PY, Phillips C, Loughnan G, Steinbeck K, Grunstein RR. Assessment of sleep and breathing in adults with prader-willi syndrome: a case control series. J Clin Sleep Med 2007; 3:713-8.

8. Larkin EK, Patel SR, Goodloe RJ, Li Y, Zhu X, Gray-McGuire C, Adams MD, Redline S. A candidate gene study of obstructive sleep apnea in European Americans and African Americans. Am J Respir Crit Care Med. 2010; 182:947-53.

9. Shiina T, Inoko H, Kulski JK. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens. 2004; 64:631-49.

10. Madden K, Chabot-Richards D. HLA testing in the molecular diagnostic laboratory. Virchows Arch. 2019; 474:139-47.

11. Gowda M, Ambardar S, Dighe N, Manjunath A, Shankaralingu C, Hirannaiah P, Harting J, Ranade S, Jagannathan L and Krishna S. Comparative Analyses of Low, Medium and High-Resolution HLA Typing Technologies for Human Populations. J Clin Cell Immunol 2016; 7:2.

12. Pataka A, Daskalopoulou E, Kalamaras G, Fekete Passa K, Argyropoulou P. Evaluation of five different questionnaires for assessing sleep apnea syndrome in a sleep clinic. Sleep Med. 2014; 15:776-81.

13. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Respirology. 2017; 22:575-601.

14. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, Troester MT, Vaughn BV. AASM scoring manual updates for 2017 (Version 2.4). J Clin Sleep Med. 2017; 13:665-6.

15. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014; 146:1387-94.

16. Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath. 2008; 12:161-8.

17. Wang C, Krishnakumar S, Wilhelmy J, Babrzadeh F, Stepanyan L, Su LF, Levinson D, Fernandez-Viña MA, Davis RW, Davis MM, Mindrinos M. High-throughput, high-fidelity HLA genotyping with deep sequencing. Proc Natl Acad Sci USA. 2012; 109:8676-81.
18. https://www.immucor.com/en-us/Products/Pages/MIA-FORA-NGS.aspx.UTR, untranslated region.
19. Robinson J, Soormally AR, Hayhurst JD, Marsh SGE. The IPD-IMGT/HLA Database-New developments in reporting HLA variation. Hum Immunol. 2016; 77:233-7.
20. Yoshizawa T, Akashiba T, Kurashina K, Otsuka K, Horie T. Genetics and obstructive sleep apnea syndrome: a study of human leukocyte antigen (HLA) typing. Intern Med. 1993; 32:94-7.
21. Lee SH, Kim CH, Ahn JH, Kang JH, Kim KH, Song JS, Park SH, Moon HS, Choi HB, Kim TG, Choi YM. Analysis of HLA in Patients with Obstructive Sleep Apnea Syndrome. Tuberc Respir Dis. 2005; 59:298-05.
22. Silva L, Lopes J, Ramalheira J, Cunha D, Carvalho C, Bettencourt A, Bras S, Costa S, Silva MB, Martins-da-Silva A. Obstructive sleep apnoea syndrome and HLA in the North of Portugal. Rev Neurol. 2015; 61:301-7.
23. Manzotte T, Guindalini C, Mazzotti DR, Palombini L, de Souza AL, Poyares D, Bittencourt LR, Tufik S. The human leucocyte antigen DQB1*0602 allele is associated with electroencephelograph differences in individuals with obstructive sleep apnoea syndrome. J Sleep Res. 2013;22 :217-22.
24. Momany SM, Al-Qatarneh TA, Khader YS, Abu-Harfeil NM, Daoud AK, Mahasneh AA. The association of HLA-DQB1*0602 but not HLA-DRB1*15 with obstructive sleep apnea. Clin Invest Med. 2017; 40: E167-E175.

25. Brunetti L, Francavilla R, Leonardo Miniello V, Leone M, Rana M, Colazzo D, Logrillo P, Favoino B, Armenio L. Influence of HLA antigens and OSAS in childhood: a preliminary report. J Sleep Res. 2005; 14:157-62.
26. Alfazer S, Cuhadaroğlu C, Tulek B, Aydemir N, Erelel M, Erkan F. Uyku apne/hipopne sendromu genetik ilişkisi: HLA doku grubu analizi. Solunum 2003; 5(2):54-8.
27. Tepebaşı MY, Şahin Calapoğlu N, Öztürk Ö, Sancer O, Gonca T. HLA-DRB1 allele frequency and immunological response in obstructive sleep apnea syndrome in Turkish population. Clin Respir J. 2018; 12:2505-12.




**Figure 1. Coverage of HLA loci using MIA FORA NGS HLA typing kit. Whole gene is sequenced for HLA-A, -B, -C and DQB1. DRB1 is sequenced for exon1 and exon2 to exon 6. Courtesy of https://www.immucor.com/en-us/Products/Pages/ MIA-FORA-NGS.aspx. UTR, untranslated region (17)**

**Table 1. The demographic characteristics and ESS data of OSA patients and normal controls.**

| | OSA(n=50) | NC (n=50) | *P* value |
|---|---|---|---|
| Age(year) | 55.8 ±4.5 | 55.72± 8.9 | 0.95 |
| Male, n (%) | 31(%62) | 31(%62) | NS |
| BMI (kg/m2) | 33.08 ±3.2 | 32.4 ± 1.9 | 0.1994 |
| ESS score | 11.5 ± 4.8 | 7.4 ± 2.4 | < 0.0001 |

Data are expressed as n (%) or mean ± standard deviation. Abbreviations: OSA-obstructive sleep apnea; NC-normal control; NS, non spesific; ESS, Epworth sleepiness scale.

**Table 2. Polysomnographic data of OSA patients**

| **Parameters** | **mean±SD** |
|---|---|
| SE (%) | 81.2 ± 55.1 |
| NREM3(%) | 6.90±1.88 |
| REM(%) | 10.8 ± 11.9 |
| AHI(event/hour) | 28.9 ± 25.6 |
| Minimum $SaO_2$ | 79.8 ± 10.9 |
| Mean $SaO_2$ | 89.6 ± 4.4 |
| t<%90 $SaO_2$ | 34.81±8.54 |

Abbreviations: AHI, apnea-hypopnea index; NREM3, the rate of non-REM sleep time to the total sleep time; REM, the rate of REM sleep time to the total sleep time; SE, the ratio of time spent asleep to time spent in bed; t SaO2 ≤ %90, the ratio of saturation spent below 90% of sleep time to the total sleep time. Data are expressed as mean ± standard deviation.

**Table 3.The six most frequent and OSA-related alleles of HLA-A, -B, -C, -DRB1, and -DQB1 loci.**

| Allele | Patients | Controls | *p* value |
|---|---|---|---|
| | allele frequency (%) | | |
| **A*02:01** | 22 | 11 | **0.036** |
| A*24:02 | 17 | 15 | 0.700 |
| A*01:01 | 10 | 17 | 0.147 |
| A*11:01 | 8 | 7 | 0.788 |
| **A*03:01** | 6 | 16 | **0.024** |
| A*68:01* | 7 | 2 | 0,088 |
| | | | |
| B*51:01 | 14 | 11 | 0.521 |
| B*18:01 | 8 | 8 | 0.602 |
| B*44:02 | 6 | 4 | 0.516 |
| B*35:01 | 6 | 7 | 0.774 |
| B*35:03 | 6 | 5 | 0.756 |
| **B*35:02** | 0 | 4 | **0.043** |
| B*44:03 | 6 | 1 | 0,054 |
| | | | |
| C*07:01 | 15 | 15 | 0.578 |
| C*04:01 | 11 | 17 | 0.221 |
| C*07:02 | 8 | 9 | 0.800 |
| C*12:03 | 8 | 10 | 0.621 |
| **C*03:03** | **7** | **0** | **0.007** |
| **C*14:03** | **4** | **0** | **0.043** |
| | | | |
| DQB1*03:01 | 29 | 32 | 0.645 |
| DQB1*03:02 | 15 | 13 | 0.684 |
| DQB1*02:01 | 11 | 16 | 0.301 |
| DQB1*06:03 | 6 | 3 | 0.306 |
| DQB1*05:01 | 6 | 7 | 0.774 |
| DQB1*06:02 | 6 | 5 | 0,756 |
| | | | |
| DRB1*11:04 | 13 | 12 | 0.831 |

| | | | |
|---|---|---|---|
| DRB1*11:01 | 10 | 12 | 0.651 |
| DRB1*04:03 | 9 | 7 | 0.602 |
| DRB1*15:01 | 7 | 7 | 0.609 |
| DRB1*13:01 | 6 | 3 | 0.306 |
| **DRB1*04:05** | **6** | **0** | **0.013** |

**Tablo 4.Comparison of the results of our study and the studies in the literature evaluating the OSAS -HLA relationship.**

| | **HLA genes** | | | | | **Patient (OSA)/control** | **Method** | **Relationship** |
|---|---|---|---|---|---|---|---|---|
| | **A** | **B** | **C** | **DR** | **DQ** | | | |
| Yoshizawa et al. (1993) | + | + | + | + | | 32/32 | Standard lymphocyte mi cro-cytotoxicity test | HLA-A2 predisposing allele |
| Alzafer et al. (2003) | + | + | + | + | + | 45/28 | Standard lymphocyte mi cro-cytotoxicity test | HLA-A28, CW3 and DR15 predisposing alleles<br>HLA B27 and B13 protective allele |
| Brunetti et al.(2005) | + | + | + | + | + | 41OSA/32PH* | Standard lymphocyte mi cro-cytotoxicity test (Class I)<br>PCR/SSO (Class II) | HLA-B65 predisposing allele |
| Lee et al. (2005) | + | + | | + | | 25/200 | Standard lymphocyte mi cro-cytotoxicity test | HLA-A*11 and HLA-DRB1*09 predisposing alleles<br>DRB1*08 related with severity |
| Manzotte et al. (2013) | | | | | + **DQB1*0602 | 894 | PCR-SSP | HLA-DQB1*0602-predisposing allele |
| Silva et al.(2015) | | | | + ** DRB1 | | 131/ 223 | PCR-SSP | DRB1*03-predisposing allele |
| Momany et al.(2017) | | | | + ** DRB1*15 | + ** DQB1*0602 | 40/40 | PCR-SSP | HLA-DQB1*0602-predisposing allele HLA-DRB1*15 unrelated allele |
| Tepebaşı et al.(2018) | | | | + | | 64/32 | PCR-SSP | DRB1*03 predisposing allele<br>DRB1*08 related with severity |
| Present Study | + | + | + | + | + | 50/50 | NGS | HLA-A*02:01,<br>HLA-C*03:03:01,<br>HLA-C*14:03 and<br>HLA DRB1*04:05 predisposing alleles<br>HLA-A*03:01 and HLA-B*35:02, protective alleles |

*PH:pulmonary hypertension, **Only one allel evaluated in these studies.